<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04041362</url>
  </required_header>
  <id_info>
    <org_study_id>UBP-A213-HIV</org_study_id>
    <nct_id>NCT04041362</nct_id>
  </id_info>
  <brief_title>the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients</brief_title>
  <official_title>A Phase II, Open-label, Controlled, Proof-of-concept Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assess the safety, tolerability, and efficacy in reducing viral load and proviral
      DNA of UB-421 administered as an add-on to the ART in ART-experienced viremic HIV-1 subjects.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study will not be submitted to authority for IND application.
  </why_stopped>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatment related TEAEs</measure>
    <time_frame>16 Weeks</time_frame>
    <description>the incidence of Grade 3 drug-related treatment-emergent adverse events</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Arm1 (Standard ART)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard ART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (ART plus UB-421)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ART plus weekly UB-421 IV infusion at 5 mg/kg dose level for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-421</intervention_name>
    <description>Monoclonal antibody by IV infusion plus standard ART</description>
    <arm_group_label>Arm 2 (ART plus UB-421)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antiretroviral Therapy (ART)</intervention_name>
    <description>Standard ART</description>
    <arm_group_label>Arm 2 (ART plus UB-421)</arm_group_label>
    <arm_group_label>Arm1 (Standard ART)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 seropositive

          2. Male with body weight ≥ 50 kg or female with body weight ≥ 45 kg.

          3. have been receiving antiretroviral therapy (ART) for more than 2 years

        Exclusion Criteria:

          1. Any previous exposure to a mAb within 12 weeks prior to the first dose of UB-421
             treatment.

          2. Any significant diseases (other than HIV-1 infection) or clinically significant
             findings, including psychiatric and behavioral problems, determined during the
             screening period, medical history, and/or physical examination that, in Investigator's
             opinion, would preclude the subject from participating in this study.

          3. History of anaphylaxis to monoclonal antibodies.

          4. Any vaccination within 8 weeks prior to the first dose of UB-421.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>UB-421</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

